Literature DB >> 18300354

Screening serum hepatocellular carcinoma-associated proteins by SELDI-based protein spectrum analysis.

Jie-Feng Cui1, Yin-Kun Liu, Hai-Jun Zhou, Xiao-Nan Kang, Cheng Huang, Yi-Feng He, Zhao-You Tang, Toshimasa Uemura.   

Abstract

AIM: To find out potential serum hepatocellular carcinoma (HCC)-associated proteins with low molecular weight and low abundance by SELDI-based serum protein spectra analysis, that will have much application in the diagnosis or differentiated diagnosis of HCC, as well as giving a better understanding of the mechanism of hepato-carcinogenesis.
METHODS: Total serum samples were collected with informed consent from 81 HCC patients with HBV(+)/cirrhosis(+), 36 cirrhosis patients and 43 chronic hepatitis B patients. Serum protein fingerprint profiles were first generated by selected WCX2 protein chip capture integrating with SELDI-TOF-MS, then normalized and aligned by Ciphergen SELDI Software 3.1.1 with Biomarker Wizard. Comparative analysis of the intensity of corresponding protein fingerprint peaks in normalized protein spectra, some protein peaks with significant difference between HCC and cirrhosis or chronic hepatitis B were found.
RESULTS: One hundred and twenty-eight serum protein peaks between 2000 and 30000 Da were identified under the condition of signal-to-noise > 5 and minimum threshold for cluster > 20%. Eighty-seven of these proteins were showed significant differences in intensity between HCC and cirrhosis (P < 0.05). Of the above differential proteins, 45 proteins had changes greater than two-fold, including 15 upregulated proteins and 30 downregulated proteins in HCC serum. Between HCC and chronic hepatitis B, 9 of 52 differential proteins (P < 0.05) had intensities of more than two-fold, including 2 upregulated proteins and 7 downregulated proteins in HCC serum. Between cirrhosis and chronic hepatitis B, 28 of 79 significant differential proteins (P < 0.05) changes greater than two-fold in intensity, including 17 upregulated proteins and 11 downregulated proteins in cirrhosis serum. For the analysis of these leading differential proteins in subtraction difference mode among three diseases, the five common downregulated proteins in HCC serum (M/Z 2870, 3941, 2688, 3165, 5483) and two common upregulated proteins (M/Z 3588, 2017) in HCC and cirrhosis serum were screened.
CONCLUSION: Because the interference of unspecific secreted proteins from hepatitis B and cirrhosis could be eliminated partly in HCC serum under subtraction difference analysis, these seven common differential proteins have the obvious advantage of specificity for evaluating the pathological state of HCC and might become novel candidate biomarkers in the diagnosis of HCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18300354      PMCID: PMC2690676          DOI: 10.3748/wjg.14.1257

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

Review 1.  Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening.

Authors:  Caroline Whitehouse; Ellen Solomon
Journal:  Gynecol Oncol       Date:  2003-01       Impact factor: 5.482

Review 2.  The human plasma proteome: history, character, and diagnostic prospects.

Authors:  N Leigh Anderson; Norman G Anderson
Journal:  Mol Cell Proteomics       Date:  2002-11       Impact factor: 5.911

3.  Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification.

Authors:  Jiefeng Cui; Xiaonan Kang; Zhi Dai; Cheng Huang; Haijun Zhou; Kun Guo; Yan Li; Yu Zhang; Ruixia Sun; Jie Chen; Yang Li; Zhaoyou Tang; Toshimasa Uemura; Yinkun Liu
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-22       Impact factor: 4.553

Review 4.  Global cancer statistics in the year 2000.

Authors:  D M Parkin
Journal:  Lancet Oncol       Date:  2001-09       Impact factor: 41.316

5.  Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.

Authors:  Rutao Cui; Baoen Wang; Huiguo Ding; Hong Shen; Yimei Li; Xiaohong Chen
Journal:  Chin Med J (Engl)       Date:  2002-01       Impact factor: 2.628

6.  Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.

Authors:  Jorge A Marrero; Grace L Su; Wei Wei; Dawn Emick; Hari S Conjeevaram; Robert J Fontana; Anna S Lok
Journal:  Hepatology       Date:  2003-05       Impact factor: 17.425

7.  The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA.

Authors:  David J Grossklaus; Joseph A Smith; Scott B Shappell; Christopher S Coffey; Sam S Chang; Michael S Cookson
Journal:  Urol Oncol       Date:  2002 Sep-Oct       Impact factor: 3.498

8.  Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma.

Authors:  Maurizio Soresi; Carmela Magliarisi; Pietro Campagna; Gaetano Leto; Giulio Bonfissuto; Anna Riili; Antonio Carroccio; Roberta Sesti; Silvio Tripi; Giuseppe Montalto
Journal:  Anticancer Res       Date:  2003 Mar-Apr       Impact factor: 2.480

Review 9.  Molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Xin W Wang; S Perwez Hussain; Teh-Ia Huo; Chuan-Ging Wu; Marshonna Forgues; Lorne J Hofseth; Christian Brechot; Curtis C Harris
Journal:  Toxicology       Date:  2002-12-27       Impact factor: 4.221

10.  Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma.

Authors:  V V Khien; H V Mao; T T Chinh; P T Ha; M H Bang; B V Lac; T V Hop; N A Tuan; L V Don; K Taketa; S Satomura
Journal:  Int J Biol Markers       Date:  2001 Apr-Jun       Impact factor: 3.248

View more
  5 in total

1.  Identification of serum amyloid A in the serum of gastric cancer patients by protein expression profiling.

Authors:  Chibo Liu; Chunqin Pan; Jianmin Shen; Haibao Wang; Liang Yong
Journal:  Oncol Lett       Date:  2012-03-30       Impact factor: 2.967

Review 2.  The application of SELDI-TOF-MS in clinical diagnosis of cancers.

Authors:  Chibo Liu
Journal:  J Biomed Biotechnol       Date:  2011-05-23

3.  Classification of Traditional Chinese Medicine Syndromes in Patients with Chronic Hepatitis B by SELDI-Based ProteinChip Analysis.

Authors:  Ya-Nan Song; Hui Zhang; Yan Guan; Jing-Hua Peng; Yi-Yu Lu; Yi-Yang Hu; Shi-Bing Su
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-30       Impact factor: 2.629

Review 4.  The current state of proteomics in GI oncology.

Authors:  Ying Lin; William S Dynan; Jeffrey R Lee; Zhao-Hua Zhu; Robert R Schade
Journal:  Dig Dis Sci       Date:  2008-12-23       Impact factor: 3.199

5.  Identification of Serum Biomarkers for Biliary Tract Cancers by a Proteomic Approach Based on Time-of-Flight Mass Spectrometry.

Authors:  Wen-Jing Wang; Wang-Hong Xu; Cha-Zhen Liu; Asif Rashid; Jia-Rong Cheng; Ping Liao; Heng Hu; Lisa W Chu; Yu-Tang Gao; Kai Yu; Ann W Hsing
Journal:  Cancers (Basel)       Date:  2010-08-18       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.